CAL101 (tidligere AX-202)

Offentlig prosjektsammendrag

Arxx is leveraging more than 30 years of research by its scientific co-founders uncovering the pathobiology of S100A4; a Damage Associated Molecular Pattern (DAMP) protein upregulated upon stress or injury allowing cells to sense and react to danger. In chronically diseased tissue, S100A4 is inappropriately activated, leading to persistent inflammation and non-resolving tissue fibrosis. Arxx is currently developing CAL101 (previously named AX-202) as a therapeutic treatment for chronic inflammatory and fibrotic disease, including idiopathic pulmonary fibrosis (IPF). IPF is a chronic and fatal lung disease. Current treatments slow disease progression but are hampered by poor tolerability and have little benefit on quality of life. Despite recent advances in the pipeline of new investigational therapies, there is still a medical need for additional therapies that are effective and well tolerated.